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                                                                     A 12-Week, Randomized, Controlled Trial With a 
4-Week Randomized Withdrawal Period to Evaluate 
the Efﬁ  cacy and Safety of Linaclotide in Irritable 
Bowel Syndrome With Constipation             
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    OBJECTIVES:       Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was 
to determine the efﬁ  cacy and safety of linaclotide in patients with irritable bowel syndrome with 
constipation (IBS-C). 
    METHODS:       This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to 
placebo or 290      μ  g oral linaclotide once daily in a 12-week treatment period, followed by a 4-week 
randomized withdrawal (RW) period. There were four primary end points, the Food and Drug 
Administration  ’  s (FDA  ’  s) primary end point for IBS-C (responder: improvement of   ≥  30  %   in average 
daily worst abdominal pain score and increase by   ≥  1 complete spontaneous bowel movement (CSBM) 
from baseline (same week) for at least 50  %   of weeks assessed) and three other primary end points, 
based on improvements in abdominal pain and CSBMs for 9  /  12 weeks. Adverse events (AEs) were 
monitored. 
    RESULTS:       The trial evaluated 800 patients (mean age      =      43.5 years, female      =      90.5  %  , white      =      76.9  %  ). The FDA 
end point was met by 136  /  405 linaclotide-treated patients (33.6  %  ), compared with 83  /  395 
placebo-treated patients (21.0  %  ) (  P        <      0.0001) (number needed to treat: 8.0, 95  %   conﬁ  dence 
interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, 
reported for at least 6  /  12 treatment period weeks, a reduction of   ≥  30  %   in abdominal pain (50.1 
vs. 37.5  %  ,   P        =      0.0003) and an increase of   ≥  1 CSBM from baseline (48.6 vs. 29.6  %  ,   P        <      0.0001). 
A greater percentage of linaclotide patients vs. placebo patients were also responders for the other 
three primary end points (  P        <      0.05). Signiﬁ  cantly greater improvements were seen in linaclotide 
vs. placebo patients for all secondary end points (  P        <      0.001). During the RW period, patients 
remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide 
to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. 
Diarrhea, the most common AE, resulted in discontinuation of 5.7  %   of linaclotide and 0.3  %   of 
placebo patients. 
    CONCLUSIONS:       Linaclotide signiﬁ  cantly improved abdominal pain and bowel symptoms associated with IBS-C for at 
least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of 
linaclotide during the RW period.   
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  Linaclotide in IBS-C 
  INTRODUCTION 
  Irritable bowel syndrome (IBS) is a common gastrointestinal 
disorder characterized by frequent and intermittent episodes of 
abdominal pain and abdominal discomfort that are associated with 
altered bowel habits ( 1,2 ). Th   e symptoms of IBS not only adversely 
aff  ect a patient  ’  s health-related quality of life (  3  ) but also place a 
signifi  cant fi  nancial burden on society due to reduced work pro-
ductivity and increased use of healthcare-related resources (  4,5  ). 
IBS with constipation (IBS-C) aff  ects approximately one-third of 
IBS patients (  3  ), occurs more commonly in women than men (  6  ), 
and frequently includes additional symptoms, such as abdomi-
nal bloating, hard stools, straining, and sensation of incomplete 
evacuation  ( 7,8 ). 
  Traditional therapies for IBS-C, generally directed towards the 
patient ’ s predominant symptoms ( 9 ), are frequently associated with 
patient dissatisfaction ( 10 ). More recent therapies, including tegas-
erod and lubiprostone, have been shown to improve global symp-
toms of IBS-C (  9  ). Tegaserod, a 5-HT  4   partial agonist approved 
by the Food and Drug Administration (FDA) for the short-term 
treatment of women with IBS-C, was removed from the market 
in 2007 due to increased cardiovascular events in patients receiv-
ing the medication. Lubiprostone, a chloride channel activator that 
was approved by the FDA for the treatment of women with IBS-C 
in 2008, has shown effi   cacy using a global end point (global symp-
tom relief) (  11  ). Given the limited treatments currently available 
for patients with IBS-C, additional therapeutic options would be 
of value. 
  Linaclotide, a minimally absorbed 14-amino-acid peptide 
structurally related to the endogenous guanylin peptide family 
of hormones that regulate fl  uid and electrolyte homeostasis in 
the intestine, binds to and activates GCC (guanylate cyclase-C) 
on the luminal surface of the intestinal epithelium. Activation 
of GCC results in the generation of cyclic guanosine mono-
phosphate (cGMP), which is increased in both the intracel-
lular and extracellular compartments. Th  e increase in cGMP 
within intestinal epithelial cells triggers a signal transduction 
cascade activating the cystic fi  brosis transmembrane conduct-
ance regulator (  12  ). Th   is activation causes secretion of chloride 
and bicarbonate into the intestinal lumen; sodium ions and 
water follow, resulting in increased luminal fl  uid secretion and 
a refl  ex acceleration of intestinal transit. Extracellular cGMP, 
actively transported out of intestinal epithelial cells, is believed 
to reduce visceral hyperalgesia by modulating the activity of 
aff  erent pain fi  bers (  13  ). In animal models, linaclotide treat-
ment accelerated gastrointestinal transit and reduced visceral 
nociception (  14  ); in human phase 2 clinical studies, it accele-
rated colonic transit (  15  ) and improved abdominal pain and 
constipation associated with IBS-C (  16  ). Likewise, in two large 
phase 3 trials in patients with chronic constipation, linaclotide 
signifi  cantly improved bowel and abdominal symptoms over 
12 weeks (  17  ). 
 Th  e objective of this phase 3 clinical trial was to assess the 
effi     cacy and safety of linaclotide administered once daily as 
an oral capsule at a dose of 290        μ  g vs. placebo to patients with 
IBS-C. A 4-week randomized withdrawal (RW) period was 
included in this trial to assess the eff  ect of discontinuing treat-
ment with linaclotide.     
  METHODS   
  Trial design 
 Th  is multicenter, randomized, double-blind, placebo-control-
led, parallel-group trial was conducted at 118 outpatient clinical 
research centers (111 in the United States, 7 in Canada) from 14 
July 2009 (fi  rst patient enrolled) to 12 July 2010 (last patient com-
pleted). Th  e protocol and all trial procedures were approved by 
an Institutional Review Board, and the trial was designed, con-
ducted, and reported in accordance with the principles of Good 
Clinical Practice guidelines. All patients gave written informed 
consent before their participation in the trial. 
 Aft  er a screening period of up to 21 days followed by a pre-
treatment baseline period of 14  –  21 days, eligible patients were 
randomly assigned with the use of an interactive voice-response 
system (IVRS) to receive once daily an oral capsule of either 
linaclotide 290       μ  g or placebo, in a 1:1 ratio. Patients who com-
pleted all 12 weeks of the double-blind treatment period were 
eligible to enter the double-blind 4-week RW period in which 
patients initially randomized to linaclotide were re-randomized 
(1:1) to linaclotide 290        μ  g or placebo, and patients previously 
randomized to placebo were assigned to receive linaclotide 
290    μ  g once a day. Randomization assignments were generated 
in blocks of four and stratifi  ed according to trial center. All spon-
sor staff   involved in the trial, trial center personnel, and patients 
were blinded to the allocation of trial treatment. Trial visits were 
conducted at screening, at the start of the pretreatment base-
line period, at randomization (day 1), throughout the treatment 
period (weeks 2, 4, 8, and 12), and at the beginning and end 
of the RW period (weeks 13 and 16 (end of trial)). Patients 
made daily calls to the IVRS to report their symptoms through-
out the trial.     
  Trial patients 
 Female and male patients were eligible to participate if they were 
at least 18 years of age, and met modifi  ed Rome II criteria for 
IBS (  18  ). In the 12 months before the screening visit, eligible 
patients were to have for at least 12 weeks, which need not be 
consecutive, abdominal pain, or abdominal discomfort that 
had   ≥  2 of these three features: (i) relieved with defecation, (ii) 
onset associated with a change in frequency of stool, and (iii) 
onset associated with a change in form (appearance) of stool, 
before starting chronic treatment with tegaserod or lubiprostone 
(if patients had taken these medications); and        <       3 spontaneous 
bowel  movements  (SBMs)  per  week  (SBM    =    a  bowel  move-
ment (BM) occurring in the absence of any laxative, supposi-
tory, or enema use during the preceding 24     h), and had at least 
one additional bowel symptom (straining, lumpy or hard stools, 
and  sensation  of  incomplete  evacuation  during      >    25 %   of  BMs), 
before starting chronic treatment with tegaserod, lubipros-
tone, polyethylene glycol 3350, or any laxative (if patients had 
taken these medications). In addition, patients had to report an The American Journal of GASTROENTEROLOGY  VOLUME 107 | NOVEMBER 2012   www.amjgastro.com
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  Rao   et al.   
average score   ≥  3.0 for daily abdominal pain at its worst (11-
point NRS (numerical rating scale)) as well as an average of        <       3 
complete SBMs (CSBMs) per week (CSBM       =       an SBM associated 
with a sense of complete evacuation, as reported by the patient) 
and   ≤  5 SBMs per week during the 14 days immediately before 
randomization (i.e., the baseline period). 
  Patients were excluded if they reported loose (mushy) or 
watery stools for        >       25  %   of their BMs during the 12 weeks before 
screening or, during the baseline period, a BSFS (Bristol Stool 
Form Scale) (  19  ) score of 7 (watery, no solid pieces) for any SBM, 
or a BSFS score of 6 (fl  uff  y pieces with ragged edges, a mushy 
stool)  for      >    1  SBM.  Other  key  exclusion  criteria  included  history 
of cathartic colon, laxative or enema abuse, ischemic colitis, or 
pelvic fl  oor dysfunction (unless successful treatment had been 
documented by a normal balloon expulsion test); bariatric sur-
gery for treatment of obesity or surgery to remove a segment of 
the gastrointestinal tract at any time before the screening visit, 
surgery of the abdomen, pelvis, or retroperitoneal structures 
during the 6 months before the screening visit, appendectomy 
or cholecystectomy during the 60 days before the screening visit, 
or other major surgery during the 30 days before the screen-
ing visit; history of diverticulitis or any chronic condition that 
could be associated with abdominal pain or discomfort and 
could confound the assessments in the trial (e.g., infl  ammatory 
bowel disease, chronic pancreatitis, polycystic kidney disease, 
ovarian cysts, endometriosis, lactose intolerance); family history 
of a familial form of colorectal cancer. In general, patients were 
excluded if they were taking drugs that could cause constipation 
(e.g., narcotics); however, patients taking certain drugs for IBS 
that might be constipating (e.g., tricyclic antidepressants) were 
eligible provided that they were on a stable dose for at least 30 
days before the screening visit and there was no plan to change 
the dose aft  er the screening visit. Colonoscopy requirements were 
based on the American Gastroenterological Association guide-
lines (  20  ). Women of childbearing potential were required to use 
contraceptives and have a negative serum pregnancy test. Patients 
were asked to refrain from making any major lifestyle changes 
(e.g., starting a new diet or changing their exercise pattern) 
during the trial. 
  Rescue medication (bisacodyl 5     mg tablet or 10     mg suppository) 
was allowed for severe constipation (i.e., 72      h aft  er the patient  ’  s 
previous BM or when symptoms became intolerable). Use of res-
cue medication was not allowed on the day before, the day of, and 
the calendar day aft  er the randomization visit. Patients on a stable, 
continuous regimen of fi  ber, bulk laxatives, stool soft  eners, or pro-
biotics during the 30 days before the screening visit were allowed 
to continue, provided they maintained a stable dosage throughout 
the trial.     
  Efﬁ  cacy assessments and end points 
  Daily reports by patients to IVRS included symptom ratings of 
worst abdominal pain, abdominal discomfort, abdominal cramp-
ing, abdominal fullness, and abdominal bloating (all abdominal 
symptoms were measured using an 11-point NRS), as well as 
the number of BMs and whether rescue medication was used. 
Each BM was assessed for sensation of complete bowel empty-
ing  (yes / no),  stool  consistency  (7-point  BSFS  with  1    =     “ separate 
hard  lumps  like  nuts ”   to  7    =     “ watery,  no  solid  pieces ” ),  and  sever-
ity of straining (5-point ordinal scale). Weekly IVRS assessments 
included IBS severity and constipation severity (both using a 5-
point ordinal scale), degree of IBS relief (7-point balanced scale), 
and adequate relief of IBS-C symptoms (yes  /  no). Assessment of 
satisfaction with the trial-medication  ’  s ability to relieve IBS symp-
toms (5-point ordinal scale) was captured at all study visits follow-
ing randomization.   
  Primary end points   .     Th  ere were four prespecifi  ed primary end 
points in the trial, which were all responder end points. One of 
the four primary end points was based on the FDA recommenda-
tions for IBS-C trial design and end points in the recently fi  nal-
ized guidance for IBS clinical trials (May 2012) (  21  ); a responder 
for this end point (to be referred to hereaft   er  as   “ FDA  end  point ” ) 
was defi  ned as a patient who met both of the following criteria 
in the same week for at least 6 of the 12 weeks of the treatment 
period: (i) an improvement of   ≥ 30 %   from  baseline  in  the  average 
of the daily worst abdominal pain scores (to be referred to here-
aft  er as   “  abdominal pain  ”  ) and (ii) an increase of   ≥ 1  CSBM  from 
baseline. Th   is combined end point was added aft  er the initiation 
of the trial, but before completion of enrollment and database 
lock, with a protocol amendment (no unblinding had occurred). 
Th   e other three primary end points also required patients to meet 
weekly responder defi  nitions, but for at least 9 of the 12 weeks of 
the treatment period. Th   ese weekly responder defi  nitions were (i) 
an improvement of   ≥  30  %   in abdominal pain, (ii)   ≥ 3  CSBMs  and 
an increase of   ≥  1 CSBM from baseline, and (iii) a combined end 
point that defi  ned a responder as a patient who met criteria for 
both i and ii in the same week.     
  Secondary end points   .     Th  e secondary end points included 
12-week change from baseline in abdominal pain, abdominal 
discomfort, abdominal bloating, stool frequency (CSBM and 
SBM weekly rates), stool consistency (BSFS), and severity of 
straining; secondary responder end points included abdomi-
nal pain and CSBM responders (using the individual compo-
nents of the FDA end point). A number of other additional end 
points were also assessed, including 12-week change from 
baseline in abdominal fullness and abdominal cramping, IBS 
symptom severity, constipation severity, adequate relief of 
IBS-C symptoms, degree of relief of IBS symptoms, and treat-
ment  satisfaction.    
  Safety assessments 
  At each scheduled study visit, all patients were asked an open-
ended question regarding adverse events (AEs). Patients reported 
AEs by recalling instances since the prior visit. Th   e site investiga-
tor assessed all patient-reported AEs and judged each event for 
severity and relationship to the blinded trial medication. Other 
safety evaluations included physical examinations, electrocardio-
gram recordings, vital sign measurements, and standard clinical 
laboratory  tests.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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    Figure 1  .                 Patient ﬂ  ow through the study.   
  Pharmacokinetic assessments 
  During the treatment period, a subset of patients had blood 
samples taken at the randomization and week 4 visits to deter-
mine if linaclotide or its active metabolite, MM 419447, could 
be detected at quantifi  able levels in the plasma.     
  Statistical methods and data analysis 
 Th   e overall family-wise type I error rate for testing the primary 
and secondary effi   cacy end points was controlled at the 0.05 
signifi   cance level using a fi   ve-step serial gate-keeping, multi-
ple-comparison procedure. Based on this multiple-comparison 
procedure and the results of a previous phase 2b study (  16  ), 
a sample size of 400 patients per treatment arm was selected to 
provide >85  %   overall power to simultaneously detect a diff  er-
ence between the placebo and linaclotide groups for the primary 
end points. 
  Responder end points were analyzed using a Cochran  – 
Mantel  –  Haenszel (CMH) test controlling for geographic region. 
Continuous change-from-baseline end points were analyzed using 
an ANCOVA (analysis of covariance) model with fi  xed-eff  ect terms 
for treatment group and geographic region and the correspond-
ing baseline value as a covariate. Least-squares means (i.e., means 
adjusted for the other eff  ects) from the ANCOVA model based 
on patients  ’   overall average scores (except for SBMs and CSBMs, 
for which the overall weekly rates were calculated) are presented. 
Geographic region was used as a factor in the analyses rather than 
individual trial centers due to the potential for very small numbers 
of patients at some trial centers. 
  If a patient dropped out of the trial or otherwise did not report 
effi   cacy data for a particular treatment-period week (patients were 
required to complete at least four IVRS calls during a treatment 
week), the patient was not considered a responder for that week. 
An observed-cases approach to missing data was applied to the 
change-from-baseline secondary end points, such that if a patient 
dropped out of the trial or otherwise did not report data, the aver-
age of the non-missing data over the 12 weeks of the treatment 
period was the patient  ’  s value. Patients were assumed to have not 
had BMs nor taken rescue medication if the corresponding daily The American Journal of GASTROENTEROLOGY  VOLUME 107 | NOVEMBER 2012   www.amjgastro.com
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which required improvement in abdominal pain (i.e., a reduction 
of   ≥  30  %   in abdominal pain), CSBM rate (i.e.,   ≥  3 CSBMs and an 
increase of   ≥  1 CSBM), or both for at least 9 of the 12 weeks of the 
treatment period ( Table 2 ). Th   e NNT (number needed to treat) for 
the primary end points ranged from 7.6 to 14.3. 
question was not answered. For the analysis of adequate relief, 
degree of relief of IBS symptoms, and treatment satisfaction, a last 
observation carried forward method was used. All   P   values  were 
based on two-sided tests. 
  All randomized patients who took at least one dose of trial 
medication were included in safety analyses (safety popula-
tion). Effi   cacy analyses were based on the ITT (intent-to-treat) 
population, which included all patients in the safety population 
who had at least one post-randomization entry of the primary 
effi     cacy assessment (i.e., IVRS assessment of abdominal pain 
or  CSBMs).    
  RESULTS   
  Patient disposition, demographics, and baseline characteristics 
  Of the 2,424 patients who were screened for participation in this 
trial, 803 (33  %  ) were randomized to treatment (  Figure 1 ).  Two 
patients were randomized at more than one trial center but only 
data from the trial center in which they were fi  rst randomized 
were included in statistical analyses. Of the 802 patients who 
received double-blind trial medication (safety population), 800 
patients had at least one post-randomization entry of the pri-
mary effi   cacy assessment (ITT population). Th  e demographics 
of the ITT population are shown in   Table 1  . Following comple-
tion of the treatment period, a total of 647 (81  %  ) ITT patients 
entered the RW period of the trial, of which 645 received at 
least one dose of trial medication and were included in the RW 
population. Mean compliance with the trial-medication dosing 
(assessed by counting pills returned at trial visits) up to trial 
discontinuation / completion of the 12-week treatment period was 
95 and 94  %   for the placebo and linaclotide groups, respectively. 
Compliance with the daily IVRS call-in (patients who completed 
  ≥ 80 %  of scheduled calls) during the treatment period was 73 and 
71  %   for placebo- and linaclotide-treated patients, respectively. 
During the pretreatment baseline period, 88  %   of patients expe-
rienced abdominal pain every day and 76  %   of patients had no 
CSBMs.   
  Efﬁ  cacy results 
  For all primary and secondary effi   cacy end points, the linaclotide 
290-  μ  g group demonstrated statistically signifi  cant improvement 
compared with the placebo group, controlling for multiplicity. 
  For the individual components of the FDA end point, a signifi  -
cantly greater percentage of linaclotide-treated patients, compared 
with placebo-treated patients, reported a reduction of   ≥ 30 %   in 
abdominal pain for at least 6 out of the 12 weeks of the treatment 
period (50.1 vs. 37.5  %  ,   P     =    0.0003  ( Figure 2  )) or an increase of 
  ≥  1 CSBM from baseline for at least 6 out of the 12 weeks of the 
treatment period (48.6 vs. 29.6  %  ,   P     <    0.0001  ( Figure 2  )). A total of 
136 of 405 patients (33.6  %  ) receiving linaclotide compared with 
83 of 395 patients (21.0  %  ) receiving placebo (odds ratio: 1.9, 95  %   
confi  dence interval: 1.4, 2.7;   P     <    0.0001)  met  the  FDA  end  point 
(  Table 2 ;   Figure 2  ). A signifi  cantly greater percentage of linaclo-
tide-treated patients than placebo-treated patients also met the 
responder requirements for the other three primary end points, 
    Table 1  .       Summary of patient demographic and baseline 
characteristics (ITT population)     
       
    Placebo, 
  N   =395  
    Linaclotide 290      µ  g, 
  N   =405  
        Demographic data   
           Age (years), mean (range)    43.7 (18  –  84)   43.3 (19  –  81) 
                  ≥  65    years,   n   (  %  )   26 (6.6)    19 (4.7) 
           Sex,   n   (  %  ) 
                Female   357 (90.4)    367 (90.6) 
                Male   38 (9.6)    38 (9.4) 
           Race,   n   (  %  ) 
                White   301 (76.2)    314 (77.5) 
                Black   75 (19.0)    78 (19.3) 
                Other   19 (4.8)    13 (3.2) 
           BMI, mean (s.d.)    27.6 (6.2)    28.3 (6.4) 
        Abdominal symptoms, mean (s.d.)   
           Abdominal pain    a       5.6 (1.7)    5.7 (1.7) 
           Abdominal discomfort    a       6.0 (1.7)    6.2 (1.6) 
           Abdominal bloating    a       6.5 (1.9)    6.7 (1.8) 
           Abdominal fullness    a       6.5 (1.8)    6.8 (1.7) 
           Abdominal cramping    a       5.4 (1.9)    5.4 (1.9) 
        Bowel symptoms, mean (s.d.)   
           CSBMs  /  week   0.2 (0.5)    0.2 (0.5) 
           SBMs  /  week   1.9 (1.4)    1.9 (1.4) 
           Stool consistency    b       2.4 (1.0)    2.3 (1.0) 
           Straining    c       3.4 (0.8)    3.6 (0.8) 
      Constipation severity    d       3.7 (0.6)    3.8 (0.6) 
      IBS severity    d       3.7 (0.6)    3.7 (0.6) 
          BMI, body mass index; CSBM, complete SBM; IBS, irritable bowel syndrome; 
ITT, intent-to-treat; SBM, spontaneous bowel movement.     
      a        Assessed using an 11-point Numerical Rating Scale: 0=none; 10=very severe.     
      b        Assessed using the BSFS: 1=separate hard lumps, like nuts (hard to pass); 
2=sausage-shaped, but lumpy; 3=like a sausage but with cracks on its surface; 
4=like a sausage or snake, smooth and soft; 5=soft blobs with clear cut edges 
(passed easily); 6=ﬂ  uffy pieces with ragged edges, a mushy stool; 7=watery, 
no solid pieces (entirely liquid).     
      c        Assessed using a 5-point ordinal scale: 1=not at all; 2=a little bit; 3=a moderate 
amount; 4=a great deal; 5=an extreme amount.     
      d        Assessed using a 5-point ordinal scale: 1=none; 2=mild; 3=moderate; 
4=severe; 5=very severe.     
          All demographic characteristics were similar between treatment groups. For 
baseline clinical characteristics, signiﬁ  cant differences were observed for 
abdominal fullness (  P  =0.011), stool consistency (  P  =0.046), and straining 
(  P  =0.020).     © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Linaclotide in IBS-C 
        Figure 2  .                 FDA end point and components. FDA end point:   ≥  30  %   abdominal pain reduction and increase   ≥  1 CSBM from baseline in the same week 
for   ≥  6  /  12 weeks.   *    *    *    *    P   value       <      0.0001,   *    *    *        <      0.001 for linaclotide vs. placebo (Cochran  –  Mantel  –  Haenszel (CMH) test).   P   values met the criterion for 
statistical signiﬁ  cance based on the multiple-comparison procedure. CSBM, complete spontaneous bowel movement; FDA, Food and Drug Administration; 
Lin, linaclotide; NNT, number needed to treat.   
  Linaclotide-treated patients also experienced statistically sig-
nifi  cantly greater improvements compared with placebo-treated 
patients for the secondary and additional end points (  Table 3 ). 
During the fi  rst week of treatment and for each subsequent week of 
treatment, linaclotide-treated patients reported greater improve-
ments in worst abdominal pain and CSBM frequency compared 
with placebo-treated patients (  P     <    0.001;   Figure 3  ). At week 12, the 
mean decrease from baseline in worst abdominal pain was 2.4  %   
for linaclotide vs. 1.5  %   for placebo (  P     <    0.0001),  and  the  mean 
increase from baseline in the weekly CSBM rate was 2.4 and 0.9 for 
linaclotide and placebo, respectively (  P     <    0.0001).  At  the  end  of  the 
Treatment Period (week 12), 52  %   of linaclotide-treated patients 
      Table 2  .       Primary efﬁ  cacy parameter results (ITT population)     
        Primary efﬁ  cacy parameters       Placebo 
responder 
(  N  =395),   n   (  %  )   
    Linaclotide 
responder 
(  N  =405),   n   (  %  )       Difference   
    Odds ratio 
(95  %   CI)         P   value      a     
    NNT 
(95  %   CI)   
      FDA end point (each week,   ≥  30  %   decrease in 
worst abdominal pain      +      an increase   ≥  1 CSBM 
from baseline for at least 6  /  12 weeks) 
  83 (21.0)    136 (33.6)    12.6   1.9 (1.4, 2.7)          <      0.0001   8.0 (5.4, 15.5) 
        ≥  30  %   Decrease in worst abdominal pain (each 
week,   ≥  30  %   decrease in abdominal pain from 
baseline for at least 9  /  12 weeks) 
  107 (27.1)    139 (34.3)    7.2   1.4 (1.0, 1.9)    0.0262   13.8 (7.4, 116.1) 
        ≥  3 CSBMs and an increase of   ≥  1 CSBM (each 
week,   ≥  3 CSBM      +      an increase   ≥  1 CSBM from 
baseline for at least 9  /  12 weeks) 
  25 (6.3)    79 (19.5)    13.2   3.7 (2.3, 5.9)          <      0.0001   7.6 (5.6, 11.6) 
      Combined responder (each week   ≥  30  %   decrease 
in worst abdominal pain      +        ≥  3 CSBM      +      an increase 
  ≥  1 CSBM from baseline for at least 9  /  12 weeks) 
  20 (5.1)    49 (12.1)    7.0   2.6 (1.5, 4.5)    0.0004   14.2 (9.2, 31.3) 
          CI, conﬁ  dence interval; CSBM, complete spontaneous bowel movement; FDA, Food and Drug Administration; ITT, intent-to-treat; NNT, number needed to treat.     
      a          P   values were based on a comparison of linaclotide vs. the placebo group using the Cochran  –  Mantel  –  Haenszel test.     
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    Table 3  .       Other efﬁ  cacy parameter results (ITT population)     
       
    Placebo, 
  N   =395  
    Linaclotide 
290      µ  g,   N   =405      Difference         P   value   
    NNT 
(95  %   CI)   
        Worst abdominal pain   
           Mean (11-point NRS scale)    4.4   3.7          
               a    Change from baseline, mean    b,c             −      1.1         −      1.9         −      0.7         <      0.0001    
               a       %   of patients with   ≥  30  %   decrease in worst abdominal pain for at least 
6  /  12 weeks    d     
  37.5   50.1   12.7   0.0003   7.9 (5.1, 17.1) 
        Abdominal discomfort   
           Mean (11-point NRS scale)    4.7   4.1          
               a    Change from baseline, mean    b,c             −      1.2         −      2.0         −      0.7         <      0.0001    
             %   of patients with   ≥  30  %   decrease in abdominal discomfort for at least 6  /  12 weeks    d       37.0   48.1   11.2   0.0013   8.9 (5.6, 22.8) 
        Abdominal bloating   
           Mean (11-point NRS scale)    5.3   4.6          
               a    Change from baseline, mean    b,c             −      1.1         −      1.9         −      0.8         <      0.0001    
             %   of patients with   ≥  30  %   decrease in abdominal bloating for at least 6  /  12 weeks    d       29.9   43.5   13.6         <      0.0001   7.4 (5.0, 14.3) 
        Abdominal fullness   
           Mean (11-point NRS scale)    5.3   4.6          
           Change from baseline, mean    b,c             −      1.1         −      2.0         −      0.9         <      0.0001    
               %   of patients with   ≥  30  %   decrease in abdominal fullness for at least 
6  /  12 weeks    d     
  32.9   44.0   11.0   0.0012   9.1 (5.6, 23.0) 
        Abdominal cramping   
           Mean (11-point NRS scale)    4.1   3.5          
           Change from baseline, mean    b,c             −      1.1         −      1.7         −      0.6         <      0.0001    
               %   of patients with   ≥  30  %   decrease in abdominal cramping for at least 
6  /  12 weeks    d     
  39.5   49.9   10.4   0.0029   9.6 (5.8, 28.3) 
        CSBMs   
           Mean CSBMs  /  week   1.0   2.6          
               a    Change from baseline, mean    b,c       0.7   2.3   1.6         <      0.0001    
           CSBM   ≤  24    h ﬁ  rst dose (  %  )    c       13.2   32.3   19.2         <      0.0001   5.2 (4.0, 7.4) 
               a      %   of patients w  /   CSBM rate increase   ≥  1 per week for at least 6  /  12 weeks    d       29.6   48.6   19.0         <      0.0001   5.3 (3.9, 8.1) 
        SBMs   
           Mean SBMs  /  week   3.2   6.0          
               a    Change from baseline    b,c       1.1   3.9   2.8         <      0.0001    
           SBM   ≤  24    h after ﬁ  rst dose (  %  )    c       43.8   67.4   23.6         <      0.0001   4.2 (3.3, 5.9) 
               %   of patients w  /   SBM rate increase   ≥  2 per week from baseline for at least 6  /  12 
weeks    d     
  29.4   57.5   28.2         <      0.0001   3.6 (2.9, 4.6) 
        Stool consistency   
           Mean BSFS score (1  –  7)   3.1   4.5          
               a    Change from baseline, mean    b,c       0.7   2.1   1.4         <      0.0001    
           Mean weekly   %   of SBMs without hard or lumpy stools (BSFS   ≥  3)   60.7   79.4   18.7         <      0.0001    
        Straining   
           Mean straining score (1  –  5)   2.8   2.2          
               a    Change from baseline, mean    b,c             −      0.7         −      1.3         −      0.7         <      0.0001    
           Mean weekly   %   of SBMs without signiﬁ  cant straining (i.e., score   ≤  3)   71.7   85.3   13.6         <      0.0001    
Table continued on following page© 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
1721
 
F
U
N
C
T
I
O
N
A
L
 
G
I
 
D
I
S
O
R
D
E
R
S
 
  Linaclotide in IBS-C 
were either  “ very satisfi   ed ”  or  “ quite satisfi   ed ”  with treatment com-
pared with 23  %   of placebo-treated patients (  P     <    0.0001). 
 During the 4-week RW Period, patients who were re-randomized 
from linaclotide to placebo showed an increase in worst abdominal 
pain and a decrease in CSBMs to levels similar to those observed 
in the placebo group during the Treatment Period. Th  e patients 
who continued to take linaclotide showed sustained improvement 
in worst abdominal pain and CSBMs similar to that previously 
observed during the Treatment Period. Th   ese improvements were 
statistically signifi  cant compared to patients re-randomized to pla-
cebo for weeks 13  –  16 for CSBMs (  P     <    0.001)  and  weeks  14 – 16  for 
worst abdominal pain (  P     <    0.05).  Patients  who  switched  from  pla-
cebo to linaclotide showed levels of improvement similar to those 
experienced by linaclotide-treated patients during the Treatment 
Period (  Figure 3 ).   
  Safety 
  A total of 228 of 406 linaclotide-treated patients (56.2  %  ) reported 
at least one treatment-emergent AE (TEAE) compared with 210 
of 396 placebo-treated patients (53.0  %  ) in the 12-week treat-
ment period (  Table 4  ). Most TEAEs were mild or moderate in 
severity (93.8  %  , linaclotide; 98.1  %  , placebo). Th  e incidences of 
diarrhea (  P     <    0.0001),  fl  atulence  (  P     =    0.0084),  and  abdominal 
pain (  P     =    0.0462)  TEAEs  were  signifi  cantly greater in the lina-
clotide-treated patients compared with placebo-treated patients. 
Th  e most common TEAE in the 12-week treatment period was 
diarrhea, experienced by 19.5  %   of linaclotide-treated patients 
compared with 3.5  %   of placebo-treated patients. Th  e occur-
rences of diarrhea were reported to be mild or moderate in 71 
of 79 linaclotide-treated patients (89.9  %  ) and 13 of 14 placebo-
treated patients (92.9  %  ) who experienced diarrhea. Th   ere were no 
SAEs of diarrhea reported during the trial. None of the patients 
who reported diarrhea experienced clinically signifi  cant sequelae 
(e.g., orthostatic hypotension or dehydration). More than half of 
linaclotide-treated patients who experienced diarrhea had onset 
within the fi  rst 2 weeks of treatment. Diarrhea was the most com-
mon AE resulting in treatment discontinuation in linaclotide-
treated patients (5.7 vs. 0.3  %   in placebo-treated patients); overall, 
AEs resulted in the premature discontinuation of 32 patients 
(7.9  %  ) and 11 patients (2.8  %  ) taking linaclotide and placebo, 
respectively, in the treatment period. 
  Rates of serious AEs (SAEs) did not diff  er between linaclo-
tide and placebo groups (two patients in each group (0.5  %  )). In 
the linaclotide group, the SAEs consisted of one patient who 
    Table 3  .       Continued     
       
    Placebo, 
  N  =395   
    Linaclotide 
290      µ  g,   N  =405       Difference         P   value   
    NNT 
(95  %   CI)   
        Constipation severity   
           Mean constipation severity score (1  –  5)   3.1   2.6          
           Change from baseline, mean    b,c             −      0.6         −      1.2         −      0.6         <      0.0001    
             %   of patients with decrease of   ≥  1 for at least 6  /  12 weeks    d       42.5   59.5   17.0         <      0.0001   5.9 (4.2, 9.9) 
        IBS severity   
           Mean IBS severity score (1  –  5)   3.1   2.7          
           Change from baseline, mean    b,c             −      0.5         −      1.0         −      0.5         <      0.0001    
             %   of patients with decrease of   ≥  1 for at least 6  /  12 weeks    d       37.5   56.3   18.8         <      0.0001   5.3 (3.9, 8.3) 
        Adequate relief   
               %   of patients reporting adequate relief of IBS symptoms for at least 75  %   of the 
weeks (i.e., 9  /  12 weeks)    d     
  21.3   36.8   15.5         <      0.0001   6.4 (4.6, 10.7) 
               %   of patients reporting adequate relief of IBS symptoms for at least 50  %   of the 
weeks (i.e., 6  /  12 weeks)    d     
  34.2   48.9   14.7         <      0.0001   6.8 (4.7, 12.6) 
        Degree of relief      e     
               %   of patients reporting   “  Somewhat Relieved,  ”     “  Considerably Relieved,  ”   or 
  “  Completely Relieved  ”   for 100  %   of the weekly scores or   “  Considerably 
Relieved  ”   or   “  Completely Relieved  ”   for at least 50  %   of the weekly scores    d     
  24.3   41.2   16.9         <      0.0001   5.9 (4.3, 9.5) 
          BSFS, Bristol Stool Forms Scale; CI, conﬁ  dence interval; CSBM, complete SBM; IBS, irritable bowel syndrome; ITT, intent-to-treat; NNT, number needed to treat; NRS, 
numerical rating scale; SBM, spontaneous bowel movement.     
      a        Secondary end point.     
      b        Changes from baseline are the least-squares means from the analysis of covariance (ANCOVA) model.     
      c          P   values were based on a comparison of linaclotide vs. the placebo group using the ANCOVA model.     
      d          P   values were based on a comparison of linaclotide vs. the placebo group using the Cochran  –  Mantel  –  Haenszel test.     
      e        Degree of Relief scale: 1=completely relieved; 2=considerably relieved; 3=somewhat relieved; 4=unchanged; 5=somewhat worse; 6=considerably worse; 7=as bad as 
I can imagine.     The American Journal of GASTROENTEROLOGY  VOLUME 107 | NOVEMBER 2012   www.amjgastro.com
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experienced chronic cholecystitis and a second patient who expe-
rienced duodenitis, gastroenteritis, hiatal hernia, esophagitis, renal 
cyst, and urinary tract infection. Th   ere were no deaths during the 
treatment period; one screened patient died as a result of cardio-
respiratory arrest and ventricular fi  brillation due to a possible drug 
overdose, but this patient died before randomization and did not 
receive trial medication. 
 Th   ere were no clinically signifi  cant diff  erences between the lina-
clotide and placebo groups in the incidence of abnormal labora-
tory parameters, vital signs, or electrocardiogram parameters. 
Serum bicarbonate levels were below the lower limit of normal at 
the end of treatment in seven patients receiving linaclotide com-
pared with one patient receiving placebo. None of these patients 
reported diarrhea as an AE or other AEs that were considered to 
be related to low bicarbonate levels. 
  In the subset of patients who were assessed for linaclotide 
exposure, no quantifi   able plasma levels of linaclotide were 
detected following trial-medication dosing at the randomiza-
tion and week 4 trial visits. All patients tested (72 placebo and 64 
linaclotide) had levels lower than the limit of quantifi  cation for 
linaclotide  (    <    0.2   ng / ml)  and  its  primary  metabolite,  MM-419447 
(    <    2.0   ng / ml). 
experienced asthma and a second patient who experienced peri-
cardial eff  usion and pericarditis leading to withdrawal from the 
trial. In the placebo group, the SAEs consisted of one patient who 
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    Table 4  .       Treatment-emergent adverse events (safety population)     
        Adverse event 
(preferred term)   
    Placebo 
(  N  =396),   n   (  %  )   
    Linaclotide 290      µ  g 
(  N  =406),   n   (  %  )         P   value   
      Patients with at 
least 1 TEAE 
    210   (  53.0)       228   (  56.2)       0.3949   
      Diarrhea   14 (3.5)    79 (19.5)          <      0.0001 
      Abdominal pain    10 (2.5)    22 (5.4)    0.0462 
      Flatulence   6 (1.5)    20 (4.9)    0.0084 
      Headache   14 (3.5)    20 (4.9)    0.3825 
      Abdominal 
distension 
  3 (0.8)    9 (2.2)    0.1434 
          Treatment-emergent adverse events (TEAEs) reported in   ≥  2  %   of linaclotide-
treated patients and at an incidence greater than reported in placebo-treated 
patients during the treatment period.     
            P   value was based on a Fisher’s exact test comparing linaclotide and placebo.             
      Figure 3  .                 Weekly results for complete spontaneous bowel movement 
(CSBM) frequency (  a  ,   *    P        <      0.0001 for linaclotide patients compared with 
placebo patients for each of the 12 Treatment-Period weeks,   *    *    P        <      0.001 
for linaclotide  –  linaclotide patients compared with linaclotide  –  placebo 
patients for RW Period weeks 13  –  16); reduction in worst abdominal pain 
(  b  ,   *    P        <      0.001 for linaclotide patients compared with placebo patients for 
each of the 12 Treatment Period weeks,   *    *    P        <      0.05 for linaclotide  –  linaclotide 
patients compared with linaclotide  –  placebo patients for RW Period weeks 
14  –  16); and percent reduction in worst abdominal pain (  c  ,  *    P        <      0.001 
for linaclotide patients compared with placebo patients for each of the 
12 Treatment Period weeks,   *    *    P        <      0.05 for linaclotide  –  linaclotide patients 
compared with linaclotide  –  placebo patients for RW Period week 14). 
All   P   values were derived from an analysis of covariance model.   © 2012 by the American College of Gastroenterology  The American Journal of GASTROENTEROLOGY
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  Linaclotide in IBS-C 
  During the RW period, TEAEs occurred in 22.2  %   of linaclo-
tide – linaclotide  patients,  22.1 %   of  linaclotide – placebo  patients, 
and 30.6  %   of placebo  –  linaclotide patients. With the exceptions of 
diarrhea and abdominal pain, the incidence of TEAEs was similar 
across the three treatment sequences. Th  e incidence of diarrhea 
was 1.9, 0.6, and 11.7  %  , in linaclotide  –  linaclotide, linaclotide  – 
placebo, and placebo  –  linaclotide patients, respectively. Th  e inci-
dence of abdominal pain was 1.3  %   in the linaclotide  –  linaclotide 
patients and 2.4  %   in the placebo  –  linaclotide patients; there 
were no TEAEs of abdominal pain in the linaclotide  –  placebo 
patients. Th   ere  was  no  evidence  of   “ rebound ”   (i.e.,  worse ning 
in IBS-C symptoms compared with the baseline period in the 
linaclotide  –  placebo patients). No SAEs were reported during the 
RW  period.    
  DISCUSSION 
  In this large phase 3 clinical trial, a greater percentage of IBS-C 
patients who were treated with linaclotide achieved statistically 
signifi  cant improvement in the key symptoms of IBS-C, including 
abdominal pain and constipation, compared with placebo. Four 
primary outcomes measures were assessed, including the FDA 
end point. Th   is end point required that patients experience a ben-
efi  t of at least 30  %   when compared with baseline in abdominal 
pain and an increase of   ≥  1 CSBM from baseline in the same week 
for at least 6 out of the 12 weeks of the treatment period. In spite 
of the rigor of this end point, 33.6  %   of linaclotide-treated patients 
were responders compared with 21.0 %  of placebo-treated patients 
(  P     <    0.0001).  Furthermore,  statistically  signifi  cant diff  erences in 
responder rates were also demonstrated for the three other pri-
mary end points, which required (i) a decrease in abdominal pain 
of   ≥  30  %  , (ii) both an absolute value of   ≥  3 CSBMs and an increase 
of   ≥  1 CSBM from baseline, and (iii) both abdominal pain and 
CSBM criteria for at least 9 of the 12 weeks of the treatment 
period. 
  Although IBS is a disorder with multiple symptoms, abdominal 
pain is one of the cardinal manifestations and strongly correlates 
with IBS severity (  22  ) and utilization of healthcare resources (  23  ). 
Also, an improvement in abdominal pain of   ≥ 30 %   has  been  shown 
to be clinically important in IBS patients (  23  ), and in patients 
reporting pain relief in general (  24  ). In this trial, more than half of 
linaclotide-treated patients reported an improvement in abdomi-
nal pain of   ≥  30  %   for at least 6 out of 12 weeks compared with 
37.5  %   of placebo-treated patients, for an NNT of 7.9. Improve-
ment in abdominal pain began within the fi  rst week of therapy, 
and once reaching maximum at 6 – 8 weeks, was sustained through-
out the remainder of the treatment period. By the last week of the 
treatment period (week 12), linaclotide-treated patients reported 
a mean improvement of 43.2  %   in abdominal pain compared with 
27.5  %   for placebo-treated patients. During the 4-week RW period, 
patients re-randomized to remain on linaclotide had continued 
relief of abdominal pain, showing durability of response, while 
those re-randomized from linaclotide to placebo showed a gradual 
worsening of abdominal pain symptoms to the level experienced 
by patients receiving placebo during the treatment period, but 
without signs of a   “  rebound  ”   or worsening of symptoms relative 
to baseline. 
  In addition to abdominal pain, linaclotide improved several 
other important abdominal symptoms that are frequently 
reported by IBS-C patients, including abdominal bloating and 
abdominal discomfort, beginning during the fi  rst week of treat-
ment and continuing throughout the 12-week treatment period. 
Linaclotide also improved bowel function, including SBM and 
CSBM frequency, straining, stool consistency, and constipation 
severity. However, in contrast to the gradual improvement in 
abdominal symptoms, improvement in bowel function occurred 
more rapidly. Most linaclotide-treated patients experienced an 
SBM within 24     h of the fi  rst dose of linaclotide (67.4 vs. 43.8  %   
for placebo,   P     <    0.0001);  maximal  improvement  in  bowel  func-
tion usually occurred within the fi  rst week. Th  us,  improvement 
with linaclotide in abdominal (sensory) symptoms such as 
abdominal pain may be attributable to more than improvement 
in bowel function alone. Preclinical data suggest that cGMP, 
which is released intra- and extracellularly following GCC acti-
vation by linaclotide, can reduce the fi  ring of pain-sensing vis-
ceral aff  erent fi  bers (  13  ). Further studies are under way that may 
provide a better understanding of the mechanisms by which 
linaclotide exerts its benefi  cial eff  ects directly on abdominal 
sensory symptoms. 
  Diarrhea was the most common TEAE in linaclotide-treated 
patients and appears to be an extension of linaclotide  ’  s pharmaco-
logical eff   ects. Although diarrhea was reported in 19.5  %   of 
linaclotide-treated patients, only 2  %   reported that they had 
severe diarrhea and only 5.7  %   discontinued the drug due to 
diarrhea. Th   e incidence of SAEs was similar between linaclotide- 
and placebo-treated patients ( n     =    2 patients in each group); diarrhea 
was not reported as an SAE. 
  In conclusion, linaclotide signifi   cantly improved abdominal 
and bowel symptoms in this phase 3 trial (12-week treatment 
period    +    4-week  RW  period).      
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  Study  Highlights  
    WHAT IS CURRENT KNOWLEDGE   
   3  The hallmark symptoms of irritable bowel syndrome with 
constipation (IBS-C) are abdominal pain and constipation-
related complaints including hard stools, straining, and 
a sense of incomplete evacuation. 
   3  There are few effective treatments for IBS-C. 
   3  Linaclotide is a minimally absorbed, 14-amino-acid peptide 
guanylate cyclase-C agonist (GCCA). 
   3  In phase 2 clinical studies, linaclotide accelerated colonic 
transit and improved abdominal pain and constipation 
associated with IBS-C. 
    WHAT IS NEW HERE   
   3  In this phase 3 trial, patients treated with linaclotide 
experienced statistically signiﬁ  cant improvements in 
abdominal symptoms (including abdominal pain) and 
bowel function (including increased frequency of bowel 
movements). 
   3  Linaclotide improved other important irritable bowel 
syndrome with constipation (IBS-C) symptoms including 
bloating, stool consistency, and straining. 
   3  Linaclotide led to a signiﬁ  cantly greater proportion of 
patients reporting adequate relief of their IBS-C symptoms 
than placebo. 
   3  Patients who completed 12 weeks of linaclotide treatment 
and were then re-randomized to placebo experienced 
a return of IBS-C symptoms, without experiencing 
  “  rebound  ”   symptoms (worsening of symptoms beyond 
baseline levels). 
   3  The most common adverse event with linaclotide treatment 
was diarrhea.                      
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